Abstract

Purpose: The effects of pan – histone deacetylase (HDAC) inhibitors on cancer cells have shown that HDACs are involved in fundamental tumor biological processes such as cell cycle control, differentiation, and apoptosis. However, because of the unselective nature of these compounds, little is known about the contribution of individual HDAC family members to tumorigenesis and progression. The purpose of this study was to evaluate the role of individual HDACs in neuroblastoma tumorigenesis.

Experimental Design: We have investigated the mRNA expression of all HDAC1-11 family members in a large cohort of primary neuroblastoma samples covering the full spectrum of the disease. HDACs associated with disease stage and survival were subsequently functionally evaluated in cell culture models.

Results: Only HDAC8 expression was significantly correlated with advanced disease and metastasis and down-regulated in stage 4S neuroblastoma associated with spontaneous regression. High HDAC8 expression was associated with poor prognostic markers and poor overall and event-free survival. The knockdown of HDAC8 resulted in the inhibition of proliferation, reduced clonogenic growth, cell cycle arrest, and differentiation in cultured neuroblastoma cells. The treatment of neuroblastoma cell lines as well as short-term-culture neuroblastoma cells with an HDAC8-selective small-molecule inhibitor induced cell proliferation and clone formation, induced differentiation, and thus reproduced the HDAC8 knockdown phenotype. Global histone 4 acetylation was not affected by HDAC8 knockdown or by selective inhibitor treatment.

Conclusions: Our data point toward an important role of HDAC8 in neuroblastoma pathogenesis and identify this HDAC family member as a specific drug target for the differentiation therapy of neuroblastoma.

The pharmacologic inhibition of histone deacetylases (HDAC) is an emerging novel molecular treatment strategy in cancer therapy (1, 2). HDAC inhibitors have been shown to induce the inhibition of proliferation, apoptosis, and clonogenic growth and to promote differentiation in several cancer cell lines in vitro, and to exert antitumoral effects in mouse models (3, 4). Subsequently, clinical trials are under way to evaluate the safety and efficacy of HDAC inhibitors (1). Recently, the first substance of this class, Vorinostat (suberoylanilide hydroxamic acid), has been approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (5, 6).

The human HDAC family is composed of 18 genes: HDAC1, HDAC2, HDAC3, and HDAC8 (class I); HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10 (class II); HDAC11 (class IV); and 7 sirtuins (class III; refs. 4, 7, 8). HDAC inhibitors can act through binding the active site and chelation of the catalytic zinc ion located at its base (9–11). However, because of the highly conserved nature of the enzymatic pocket,

Authors’ Affiliations: 1Clinical Cooperation Unit Pediatric Oncology, 2Department of Biostatistics, 3Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, 4Department of Neuropathology, German Cancer Research Center, 5Department of Tumor Genetics, and 6Clinical Cooperation Unit Neuropathology, University Hospital of Heidelberg, Heidelberg, Germany; 7Department of Pediatric Oncology, University Children’s Hospital of Cologne, Cologne, Germany; 8Department of Chemistry, Ithaca College, Ithaca, New York.

Received 3/14/08; revised 6/26/08; accepted 7/22/08.

Grant support: Heinrich F.C. Behr stipend for medical students, University of Heidelberg (J-P. Linke); Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung; National Genome Research Network or Nationalen Genomforschungsnetz) grant 02KR-S19T03 and European Embryonal Tumor Pipeline (European Union) grant 037260 (F. Westermann); Deutsche Krebshilfe grants 502719 and 106847, Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung; National Genome Research Network or Nationalen Genomforschungsnetz) grant 01GS0456, and Fördergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V (M. Fischer); Deutsche Krebshilfe grants 70-443, FO-2032-B67, and 102546 (B. Hero); Research Corporation Cottrell College Science Award grant CC5955 (S. Ulrich); and Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung; National Genome Research Network or Nationalen Genomforschungsnetz) grant 01GS0459 (O. Witt). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Requests for reprints: Olaf Witt, Clinical Cooperation Unit Pediatric Oncology G340, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. Phone: 49-6221-423570; Fax: 49-6221-423277; E-mail: o.witt@dkfz.de.

© 2009 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-08-0684
Histone deacetylase (HDAC) inhibitors are an emerging class of promising novel anticancer drugs. However, little is known which of the 11 classic HDAC family members is the most relevant drug target for therapy. First phase I or II trials show that the unselective inhibition of HDACs causes a variety of side effects. Therefore, identification and selective targeting of the most critical cancer-relevant HDAC family member may reduce unspecific effects and increase antitumor efficacy in the future. This work describes for the first time the clinical relevance of a particular HDAC family member, HDAC8, in a large study cohort of tumor patients using childhood neuroblastoma as a model. High HDAC8 expression correlates with established clinical and genetic risk factors, neuroblastoma progression, and the poor survival of patients. The selective targeting of HDAC8 causes the inhibition of cell proliferation and clonogenic growth and the induction of neuronal differentiation in culture models. Thus, the work opens novel antineuroblastoma treatment perspectives using selective HDAC8 small-molecule inhibitors.

**Materials and Methods**

**Neuroblastoma samples.** The expression of HDAC1, HDAC2, HDAC3, HDAC6, HDAC7, HDAC9, and HDAC11 was analyzed using oligonucleotide microarrays in 251 neuroblastomas as described previously (17). The expression of HDAGs not represented on the array (HDAC4, HDAC5, HDAC8, and HDAC10) as well as HDAC2 and HDAC11 was investigated by real-time reverse transcription-PCR (RT-PCR) in a cohort of 118 samples. The neuroblastomas of these 118 patients were diagnosed between the years 1989 and 2003. All patients were enrolled in the German Neuroblastoma trials with informed consent (18, 19). Clinical stage was classified according to the International Neuroblastoma Staging System (stage 1, n = 9; stage 2, n = 9; stage 3, n = 16; stage 4, n = 49; stage 4S, n = 25; ref. 20), and histopathologic prognostic category grouping was done according to the Shimada classification (21, 22). MYCN was assessed in one or more central laboratories using fluorescence in situ hybridization, PCR, and/or Southern blot techniques (H. Christiansen, Marburg; M. Schwab, Heidelberg; R. Spitz, Cologne). Aberrations (deletion, imbalance) of chromosomes 1p and 11q were assessed by fluorescence in situ hybridization as outlined previously (23, 24).

**Oligonucleotide microarray analysis.** Microarray analysis, total RNA preparation from snap-frozen neuroblastoma samples, and data acquisition and processing were done as previously published (17). For more details, see Supplementary Data. All raw and normalized microarray data are available at the ArrayExpress database (accession: E-TABM-38).  

**Real-time RT-PCR analysis of mRNA.** The real-time RT-PCR analysis of mRNA expression in tumor samples and cell lines was done as previously described (25, 26). Detailed information on primer sequences and protocols are provided in the Supplementary Data.

**Statistical analysis.** Analysis of oligonucleotide microarray data was done using Rosetta Resolver (V5.1, Rosetta Inpharmatics LLC). The patients’ subgroups of interest were compared by Benjamini-Hochberg corrected one-way ANOVA. For the comparison of expression data between different patient subgroups (1p, 11q, Shimada, MYCN, age at diagnosis), Wilcoxon rank sum test was used. ANOVA was used for comparisons in expression between disease stages. All contrasts were tested, and P values were adjusted according to Bonferroni. Kaplan-Meier estimates for survival were plotted with R (R version 2.4.1 [2006-12-18] 2006, The R Foundation for Statistical Computing, ISBN 3-900051-07-0). Cut point analysis for overall and event-free survival was done for HDAC8 using maximally selected rank statistics as implemented in the package maxstat (27) in R. For overall survival analysis, the optimal cut point for ΔΔCT values was 3.68 (maximal log-rank statistical M = 3.575; P = 0.01984). The same cut point was chosen for event-free survival (here maximal log-rank statistical M = 3.321; P = 0.04771). Five-year overall and event-free survival with confidence interval was calculated with R. For overall survival, death from any cause was counted. For event-free survival, death from any cause, relapse, progression, or second malignancy was defined as event. Cox proportional hazard model was used to investigate whether HDAC8 (dichotomized with the cut point 3.68) is a prognostic factor adjusted for the covariates 1p, 11q, Shimada, and MYCN.

To compare the same interfering RNA (siRNA) of interest with negative control siRNA, a two-tailed test of significance was done using GraphPad Prism version 3.0a. Means are represented in bar charts, and error bars represent the SD of at least three independent experiments.

**Cell lines and reagents.** Human neuroblastoma cell lines BE(2)-C, SH-SY5Y, Kelly, NGP, SH-EP, WAC2, and SK-N-BE(2) were cultured under standard conditions (see Supplementary Data).

Short-term-culture neuroblastoma cells (NB2), originally isolated from the bone marrow of a patient with metastasized stage 4 neuroblastoma (MYCN amplified) after obtaining informed consent, were cultured in DMEM with l-glutamine and 4.5 g/L glucose containing 10% fetal bovine serum and 1% nonessential amino acids (28). Selective HDAC8 inhibitor (compound 2) is described elsewhere (12). The compound was dissolved in DMSO as a stock of 250 mmol/L. Pan-HDAC inhibitors trichostatin A and valproic acid were used as previously described (26). All-rnexin retinoic acid (Sigma) was dissolved in ethanol as a stock of 10 mmol/L.

**Transfection with siRNA.** Cells (3×10^4 per well) were seeded into 6-well plates 24 h before transient transfection with 5 or 25 nmol/L...
siRNA, respectively, for 18 h using HiPerFECT according to the manufacturer’s instructions (Qiagen). For HDAC8 knockdown, the following siRNAs were used: siRNA1 [ID 120597, exon 1 and 2, Ambion (Europe) Ltd.], siRNA2 [ID 2120599, exon 5, Ambion], siRNA3 [ref. 29; sense, 5'-ACGGGCGAUGUACCAUGAUA-3'; antisense, 5'-AUGACACUAUCCUGCGCAUGT-3'], siRNA4 (Hs_HDAC8_5_HP, Qiagen), and siRNA5 (HDAC8 ON-TARGETplus SMARTpool, Dharmacon, Inc.). For HDAC2 knockdown, the following siRNAs were used: siRNA1 [ID 120208, exon 3, Ambion], siRNA2 [ID 213400, exon 2, Ambion], siRNA3 [ID 120209, exon 5, Ambion], and siRNA4 [ID 120210, exon 7 and 8, Ambion]. As negative controls, the following siRNAs were used: NC-1 (siCONTROL RISC-Free siRNA 1, Dharmacon), NC-2 (Silencer Negative Control siRNA, Qiagen). Transfection efficacy in BE(2)-C cells was 90.3% (confidence interval, 80.5-100.2%) as determined by fluorescently labeled siRNA siGLO Lamin A/C (Dharmacon).

**Overexpression of HDAC8.** An expression plasmid containing the HDAC8 cDNA sequence was cloned by using the gateway (Invitrogen) cloning system (pEX3.2-HDAC8 = pcDNA3.2/V5-DEST/C2cDNAsequencewasclonedbyusingthegateway(Invitrogen)labeledsiRNAsiGLOLaminA/C(Dharmacon).

**Results**

High HDAC8 expression is correlated with markers of poor outcome and advanced stage disease in neuroblastoma. Neuroblastoma is characterized by a broad clinical spectrum of disease ranging from localized stage I with excellent prognosis of about 90% survival to metastatic stage 4 neuroblastoma associated with poor survival of about 30%. Furthermore, stage 4S neuroblastoma is associated with spontaneous regression in most patients, despite metastasis into liver, skin, and bone marrow (16).

We investigated the mRNA expression of all 11 non-sirtuin HDAC family members in large cohorts of primary neuroblastoma samples from the German Neuroblastoma trial using oligonucleotide microarray (n = 251) or real-time RT-PCR analysis (n = 118). The comparison of HDAC1-11 expression in stage 4 versus stage 1 disease revealed that only HDAC8 expression was significantly associated with advanced-stage disease (Supplementary Table S2).

The detailed analysis of HDAC8 expression by real-time RT-PCR in 118 neuroblastoma samples covering all clinical stages, as well as defined genetic (1p and 11q aberration and MYCN amplification) and histopathologic risk groups, is shown in Fig. 1. HDAC8 expression was low in localized stages 1 to 3 but showed significantly higher expression levels in metastasized stage 4 disease (Fig. 1A). Interestingly, expression was low in metastasized stage 4S disease, known to be associated with spontaneous regression (Fig. 1A). High HDAC8 expression levels significantly correlated with 11q (Fig. 1B) and 1p (data not shown) unfavorable cytogenetic aberrations, as well as unfavorable Shimada histopathologic classification (Fig. 1C). The Shimada histopathologic classification system groups neuroblastoma patients into a favorable or unfavorable category based on the degree of differentiation of neuroblastoma cells, the amount of intercellular stroma, the mitosis-karyorrhexis index, and the patient age (34). Finally, HDAC8 expression was significantly increased in older patients (>18 months) known to be associated with unfavorable outcome (Fig. 1D). MYCN oncogene amplification was not associated with differential HDAC8 expression (data not shown). These results clearly show that among all 11 HDAC family members, only HDAC8 expression correlates with advanced disease stage but is low in stage 4S neuroblastoma known to be associated with spontaneous regression. In addition, HDAC8 expression correlates with molecular risk factors, unfavorable histopathology, and older age.

**High HDAC8 transcript levels correlate with adverse clinical outcome of neuroblastoma patients.** To determine whether HDAC8 expression levels are related to differences in patients’ outcome, Kaplan-Meier estimates for overall survival and event-free survival were calculated. As expected from the strong correlation with established prognostic markers, it turned out that high HDAC8 expression was associated with adverse clinical outcome (Fig. 2A and B). In neuroblastomas with high HDAC8 expression, 5-year overall survival was 25.9% (95% confidence interval, 8.7-77.1%) versus 77.8% (confidence interval, 8.7-86.5%) in tumors with low HDAC8 expression. Event-free survival was 25.9% (confidence interval, 8.7-77.1%).
versus 73.8% (confidence interval, 65.6-83.1%), respectively. For comparison, we have calculated survival curves of the investigated patient cohort according to the MYCN oncogene amplification status, which is an established genetic marker for neuroblastoma risk stratification (Fig. 2C and D).

Cox regression revealed that HDAC8 expression was not an independent factor for overall or event-free survival when covariates 1p aberration, 11q aberration, Shimada classification, and MYCN were included in the analysis.

Taken together, these results show that HDAC8 transcript levels discriminate neuroblastoma patients with benign and adverse outcome.

Knockdown of HDAC8 inhibits cell proliferation and clonogenic growth of neuroblastoma cells. To investigate the functional role of HDAC8 in a cell culture model, we analyzed its expression in neuroblastoma cell lines BE(2)-C, SK-N-BE(2), NGP, Kelly, WAC2, SH-EP, SH-SY5Y, and IMR32. All cells revealed detectable HDAC8 expression at the mRNA level. In addition, we did a Western blot analysis of several neuroblastoma cell lines and primary tumor samples confirming HDAC8 protein expression in all samples investigated (Supplementary Fig. S1). Immunohistochemistry of selected neuroblastoma samples revealed variable HDAC8 protein expression with a predominant cytoplasmatic staining pattern (Supplementary Fig. S1).

We selected BE(2)-C cells for further experiments because these cells (a) form colonies in soft agar, (b) possess stem cell–like characteristics with the potential to recapitulate many aspects of neuroblastoma biology (35), and (c) respond to pharmacologic HDAC inhibition with reduced proliferation and the induction of neuronal differentiation and apoptosis (32). We reduced endogenous HDAC8 expression by transiently transfecting siRNAs into BE(2)-C cells. Three different control siRNAs and five different siRNAs targeting various parts of the HDAC8 mRNA sequence were used to control for unspecific as well as off-target effects. The efficient reduction of mRNA and protein levels was obtained lasting at least 96 h (Supplementary Fig. S2).

The transfection of all HDAC8 siRNAs caused a reduction of cell proliferation compared with control transfections (Fig. 3A). The calculation of the population doubling time from estimated growth curves revealed a twice higher doubling time for HDAC8 siRNA1 – transfected BE(2)-C (50 h) cells compared with negative control – transfected cells (26 h, data not shown). To investigate the role of HDAC8 for anchorage-independent clonal growth capability, we did soft agar assays after transfection of BE(2)-C cells with siRNAs. Again, all siRNAs directed against HDAC8 produced similar results, causing a significant reduction in colony numbers compared with control transfections (Fig. 3B).

**Fig. 1.** HDAC8 expression correlates with advanced-stage disease and markers of poor outcome in neuroblastoma. A, analysis of HDAC8 expression in 118 neuroblastoma samples with real-time RT-PCR reveals significantly higher expression in International Neuroblastoma Staging System stage IV tumors compared with International Neuroblastoma Staging System stages 1 (P < 0.0001), 2 (P = 0.0229), 3 (P = 0.0006), and 4S (P = 0.0009). All contrasts are tested. The Y axis represents the relative HDAC8 mRNA expression normalized against housekeeping genes (SDHA, HPRT) and calculated relatively to the lowest expression sample, which was set to 1. ANOVA analysis showed that stage has a significant effect (P < 0.0001). Bonferroni-adjusted comparisons between the groups showed that stages 1 and 4 differ significantly (P < 0.0001), stages 2 and 4 differ significantly (P = 0.0229), stages 3 and 4 differ significantly (P = 0.0006), and stages 4 and 4S differ significantly (P = 0.0009). B, high HDAC8 expression significantly correlates with chromosome 11q (P < 0.0001). C, high HDAC8 expression significantly correlates with unfavorable Shimada histopathologic classification (P = 0.0002). Fav, favorable; unfav, unfavorable Shimada classification. D, HDAC8 expression significantly correlates with patient’s age at diagnosis. Patients older than 18 mo express higher levels of HDAC8 (P < 0.0001). For comparison of expression data between different patient subgroups (B-D), Wilcoxon rank sum test was used.
down-regulated (Fig. 5A). These changes could not be observed following HDAC2 knockdown of cells (data not shown). We confirmed the expression of the differentiation marker neurotrophin receptor kinase A (NTRK1/TrkA) at the protein level using Western blot analysis (Fig. 5B). Because the differentiation of cells is typically associated with a cell cycle arrest, we analyzed cell cycle distribution following HDAC8 knockdown. Indeed, we could observe a G0/G1 arrest with 85 ± 3% of cells transfected with HDAC8 siRNA1 in G0/G1 compared with 67 ± 5% negative control (NC-2)–transfected cells in G0/G1 (P < 0.0001; Fig. 5C), associated with induction of p21WAF1/CIP1 mRNA (Fig. 5D) and protein (data not shown), which is known to mediate cell cycle arrest in response to pharmacologic HDAC inhibition (36). The apoptotic phenotype observed following HDAC2 knockdown (Fig. 4A) was confirmed by a significant increase in caspase-3–like activity, nuclear condensation, and amount of cells in the sub-G1 area of the cell cycle profile (Supplementary Fig. S3). In contrast, HDAC8 knockdown did not affect the apoptosis rates (Supplementary Fig. S3). Similar results were obtained in Kelly, SH-EP, and SK-N-BE(2) neuroblastoma cells, showing the induction of differentiation markers following HDAC8 knockdown (Supplementary Fig. S4). The overexpression of HDAC8 resulted in the suppression of neurofilament and NTRK1 neurotrophin receptor expression. Furthermore, retinoic acid–induced morphologic differentiation was inhibited by HDAC8 overexpression (Supplementary Fig. S5).

Thus, HDAC8 knockdown initiates a differentiation program, whereas HDAC2 knockdown induces apoptosis in neuroblastoma cells.

**(HDAC8-selective small-molecule inhibitor as a potential compound for the differentiation therapy of neuroblastoma.** The knockdown experiments suggest that specific targeting of HDAC8 may be a novel rationale for the differentiation therapy of neuroblastoma. Recently, HDAC8-selective inhibitors were designed based on linkerless hydroxamic acids (12). These compounds show IC50 for HDAC8, which was >100-fold lower compared with other class I and II HDACs (12). Treatment with the HDAC8-selective inhibitor compound 2 at concentrations in the range of its in vitro IC50 against HDAC8 resulted in reduced cell density and outgrowth of neurite-like structures (Fig. 6A) that stained positive for neurofilament (Fig. 6B). Cell proliferation was inhibited in a concentration-dependent manner in three neuroblastoma cell lines. In addition, treatment of short-term–culture primary neuroblastoma cells derived from the bone marrow of a patient with metastasized disease with compound 2 revealed the inhibition of proliferation (Fig. 6C), which was associated with the induction of p21WAF1/CIP1 gene expression (data not shown). The influence of compound 2 on clonogenic growth was tested in BE(2)-C cells, which are able to grow anchorage independently. The HDAC8-selective inhibitor reduced the formation of clones in soft-agar concentration dependently (Fig. 6D). The HDAC8-selective nature of compound 2 is supported by the observation that the treatment of cells increased neither global histone H4 nor tubulin acetylation, which are substrates for HDAC1/2 and HDAC6, respectively (2, 13, 37). Furthermore, total intracellular HDAC activity was not reduced by compound 2 in contrast to the pan-HDAC inhibitors valproic acid and trichostatin A (Supplementary Fig. S6).
In conclusion, a HDAC8-selective small-molecule inhibitor reproduces the differentiation phenotype induced by RNA interference–mediated HDAC8 knockdown in established as well as short-term-culture primary neuroblastoma cells.

Discussion

Despite the broad application of HDAC inhibitors in preclinical models and their recent introduction in clinical trials, little is known about the cancer relevance of individual

![Fig. 3.](image) HDAC8 knockdown decreases BE(2)-C cell growth. A, HDAC8 knockdown results in significantly decreased cell numbers using five different siRNAs (black columns; siRNA1-5) and is additionally depicted as mean value (open column; mean = 29 ± 13%; P = 0.0011) compared with three negative control siRNAs (open column; NCT-3; mean = 80 ± 2%). Cell numbers are expressed relative to untreated cells. B, HDAC8 knockdown results in significant lower amounts of colonies formed in soft agar with five different siRNAs (open column; NC-1-3; mean = 73 ± 6 colonies per well). C, grown colonies stained with crystal violet from negative control siRNA (NC-1, top) and HDAC8 siRNA1 (bottom) – transfected BE(2)-C cells.

![Fig. 4.](image) HDAC8 knockdown induces a neuronal phenotype in BE(2)-C cells. A, HDAC8 knockdown induces outgrowth of neurite-like structures in BE(2)-C cells using different siRNAs (HDAC8 siRNA 1 and 2), whereas HDAC2 knockdown increases the amount of rounded, shrunken, and detached cells suggestive of cell death (HDAC2 siRNA 1 and 2). NC-1-2, cells transfected with negative control siRNAs 1 and 2. B, neurofilament staining of neurite-like structures occurring after HDAC8 knockdown using an antibody recognizing NEF-M. Top, cells transfected with negative control siRNA2 (NC-2). Bottom, cells transfected with siRNA1 targeting HDAC8.
HDAC family members. This lack of information is mainly due to the broad inhibitory activity of the commonly used HDAC compounds, making it impossible to define the responsible HDAC controlling cell proliferation, apoptosis, and differentiation. However, the identification of the cancer-relevant HDAC family members would allow the design of selective inhibitors and facilitate insights into the molecular mechanism of biological programs suppressed in cancer cells.

Based on the following observations, we propose that HDAC8 is involved in neuroblastoma pathogenesis and provides a novel specific drug target for differentiation therapy of neuroblastoma. (a) HDAC8 expression is up-regulated in advanced stage and metastasized disease and is associated with poor prognostic markers such as 1p and 11q aberration, age, and unfavorable Shimada histopathologic classification. (b) HDAC8 expression is down-regulated in stage 4S neuroblastoma known to be associated with spontaneous regression. (c) High expression correlates with poor overall survival and event-free survival of patients. (d) The knockdown of HDAC8 causes the inhibition of proliferation, reduction of clonogenic growth, and induction of cell cycle arrest and differentiation of neuroblastoma cells. Conversely, HDAC8 overexpression suppressed the endogenous expression of differentiation markers and inhibited retinoic acid–induced morphologic differentiation. (e) The treatment of neuroblastoma cells with a HDAC8-selective small-molecule inhibitor reproduced the phenotype obtained with siRNA-mediated knockdown of HDAC8 in established as well as short-term-culture neuroblastoma cells.

Little is known about the function of HDAC8. Expression analysis suggest a role in differentiation of smooth muscle cells (38). Proliferation of lung, colon, and cervical cancer cell lines is reduced after HDAC8 knockdown (39), and, recently, HDAC8 has been implicated in the regulation of telomerase activity (40).

Thus far, there are no systematic data available on the expression of HDAC1 to HDAC11 family members in a large patient cohort. Our data show for the first time that only

Fig. 5. HDAC8 knockdown induces differentiation of BE(2)-C cells. A, transfection with siRNA (siRNA1) directed against HDAC8 induces expression of differentiation markers (MAP2, NEF-M, NEF-L, NTRK1, TUBB3, GAP43, NTS) and reduction of nestin (NES), a marker for undifferentiated neural progenitor cells. Mock, cells treated with transfection reagent only; NC-2, cells transfected with negative control siRNA2. B. NTRK1 expression is confirmed on protein level with an antibody recognizing Trk (140 kDa). C, analysis of cell cycle profile reveals that HDAC8 knockdown assembles 85% cells in G0/G1 (black column), 11% in S (open column), and 4% in G2/M (hatched column), whereas transfection with NC-2 siRNA distributes 67% of cells in G0/G1, 28% of cells in S, and 8% of cells in G2/M phase of the cell cycle. The difference in G0/G1 is significant (P < 0.0001). D, the G0/G1 arrest induced by HDAC8 siRNA1 is associated with p21WAF1/CIP1 mRNA up-regulation.
HDAC8 expression significantly correlates with disease stage and progression in a large cohort of cancer patients. HDAC1 (41–43), HDAC2 (14, 15), and HDAC3 (42) have been found to be expressed at higher levels in cancer tissues in small numbers of selected clinical samples. Interestingly, HDAC1 has recently been found to be up-regulated in chemotherapy resistant neuroblastoma cells in vitro (44). Thus, the up-regulation of members of the class I HDAC family members seem to be a common theme in tumor biology.

By directly comparing the phenotype of HDAC8 and HDAC2 knockdown, we found that these family members control different cellular programs, that is, HDAC8 down-regulation releases a differentiation program whereas HDAC2 knockdown causes apoptosis. This may explain the different biological effects observed with pan-HDAC inhibitors on cancer cells. Interestingly, global histone acetylation, a widely used surrogate marker for intracellular HDAC inhibition, was not increased, and global HDAC enzymatic activity within cells was not changed following HDAC8 knockdown in contrast to HDAC2 knockdown, supporting the HDAC8-selective targeting approach in our culture models.

Taken together, our findings point toward an important role of HDAC8 in neuroblastoma pathogenesis and highlight this HDAC family member as a novel drug target for differentiation therapy.

**Note Added in Proof**

Recently, a novel HDAC8-selective compound, PCI-34051, was described (Balasubramanian et al. Leukemia 2008;22:
1026 – 34). The compound induces apoptosis in T-cell lymphoma or leukemia cell lines but not in cells derived from solid tumors, suggesting a tumor type–selective activity.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank H. Christiansen (Pediatric Oncology, University of Marburg, Marburg, Germany) and M. Schwab (Division of Tumor Genetics, German Cancer Research Center, Heidelberg, Germany) for the analysis of N-myC amplification status of tumor samples of the German Neuroblastoma trials; R. Spitz (Pediatric Oncology, University of Cologne, Cologne, Germany) for the aforementioned analysis and 1p and 1q status analysis; Angelika Knuppel for her excellent technical assistance; and Gabriele Becker for her skilful technical support in flow cytometry.

References

# Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/15/1/91">http://clincancerres.aacrjournals.org/content/15/1/91</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2009/01/07/15.1.91.DC1">http://clincancerres.aacrjournals.org/content/suppl/2009/01/07/15.1.91.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 44 articles, 13 of which you can access for free at: <a href="http://clincancerres.aacrjournals.org/content/15/1/91.full#ref-list-1">http://clincancerres.aacrjournals.org/content/15/1/91.full#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 23 HighWire-hosted articles. Access the articles at: <a href="http://clincancerres.aacrjournals.org/content/15/1/91.full#related-urls">http://clincancerres.aacrjournals.org/content/15/1/91.full#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>